JAMONY
CLDX icon

Jacob Asset Management of New York’s Celldex Therapeutics CLDX Stock Holding History

Jacob Asset Management of New York’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		$283K Sell
533
-67
-11% -$23K 0.35% 79
2013
Q2 		$140K Buy
+600
New +$118K 0.19% 114

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Jacob Asset Management of New York's CLDX Position: Q3 2013 in Review

Jacob Asset Management of New York reduced its Celldex Therapeutics (CLDX) stake by 11% in Q3 2013, selling an estimated $23K and leaving 533 shares worth $283K. The position accounts for 0.35% of the portfolio, ranked #79.

Jacob Asset Management of New York first reported a position in CLDX in Q2 2013 and has held it in 2 quarters since. 150 funds tracked by Wall St. Rank hold CLDX as of Q3 2013.

  • Jacob Asset Management of New York held 533 shares of Celldex Therapeutics worth $283K as of Q3 2013.
  • Jacob Asset Management of New York sold 67 Celldex Therapeutics shares in Q3 2013, an estimated $23K.
  • Celldex Therapeutics made up 0.35% of Jacob Asset Management of New York's portfolio in Q3 2013, its #79 holding.
  • Jacob Asset Management of New York first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 2 quarters since.
  • 150 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2013.

Based on Jacob Asset Management of New York's 13F filing for Q3 2013, filed 14 Nov 2013.